HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer

• Published in: Cancer prevention research (Philadelphia, Pa.) Vol. 13; no. 9; pp. 783 - 794
• Main Authors: Valle, Blanca L, Rodriguez-Torres, Sebastian, Kuhn, Elisabetta, Díaz-Montes, Teresa, Parrilla-Castellar, Edgardo, Lawson, Fahcina P, Folawiyo, Oluwasina, Ili-Gangas, Carmen, Brebi-Mieville, Priscilla, Eshleman, James R, Herman, James, Shih, Ie-Ming, Sidransky, David, Guerrero-Preston, Rafael
• Format: Journal Article
• Language: English
• Published: United States 01.09.2020
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Biomarkers, Tumor - genetics; Cell Line, Tumor; Cohort Studies; Cystadenocarcinoma, Serous - diagnosis; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - mortality; Decitabine - pharmacology; Decitabine - therapeutic use; DNA Methylation - drug effects; Down-Regulation; Epithelium; Fallopian Tubes - pathology; Female; Gene Expression Regulation, Neoplastic - drug effects; Guanylate Kinases - genetics; Histones - genetics; Humans; Hydroxamic Acids - pharmacology; Hydroxamic Acids - therapeutic use; Mutation; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - mortality; Ovary - pathology; Precision Medicine - methods; Promoter Regions, Genetic; Survival Analysis

Molecular alterations that contribute to long-term (LT) and short-term (ST) survival in ovarian high-grade serous carcinoma (HGSC) may be used as precision medicine biomarkers. DNA promoter methylation is an early event in tumorigenesis, which can be detected in blood and urine, making it a feasible...